|
1) Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell. 2005; 7: 129-41
|
|
|
|
2) Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354: 2542-51
|
|
|
|
|
|
3) Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-9
|
|
|
|
|
|
4) Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401
|
|
|
|
|
|
5) Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemia. N Engl J Med. 2006; 354: 2531-41
|
|
|
|
|
|
6) Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2260-70
|
|
|
|
|
|
7) Kantarjian H, OʼBrien S, Jabbour E, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011; July 11 on line
|
|
|
|
|
|
8) Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukemia. Nature. 2005; 435: 1267-70
|
|
|
|
|
|
9) Roeder I, Horn M, Glauche I, et al. Dynamics modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nature Med. 2006; 12: 1181-4
|
|
|
|
|
|
10) Cortes J, OʼBrien S, Kantarjuan H. Discontinua-tion of imatinib therapy after achieving a molecular response. Blood. 2004; 107: 2204-5
|
|
|
|
|
|
11) Merante S, Orlandi E, Bemasconi P, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Hematologica. 2005; 90: 979-81
|
|
|
|
|
|
12) Mahon FX, Rea D, Guilhot F, et al. Dis-continuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11: 1029-35
|
|
|
|
|